Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Pobilukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 17/20 | 0.89 |
| ▸ | CYSLTR1 | Q9Y271 | 17/20 | 0.89 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pobilukast SCHEMBL9508139 | 0.96 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL9508133 | 0.96 | CYSLTR2 (0.98) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL125952 | 0.94 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL6437479 | 0.94 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| Pobilukast SCHEMBL29473536 | 0.94 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL27262084 | 0.84 | CYSLTR2 (0.81) | CYSLTR2CYSLTR1 | |
| SCHEMBL9395596 | 0.84 | CYSLTR2 (0.81) | CYSLTR2CYSLTR1 | |
| SCHEMBL9395589 | 0.84 | CYSLTR2 (0.81) | CYSLTR2CYSLTR1 | |
| SCHEMBL9301491 | 0.83 | CYSLTR2 (0.78) | CYSLTR2CYSLTR1MAPTRXFP1 | |
| SCHEMBL9560386 | 0.83 | CYSLTR2 (0.74) | CYSLTR2CYSLTR1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6935334-B2 | Enhancing therapeutic effectiveness of nitric oxide inhalation | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-30 | — | — | US | claimed |
| EP-1301076-A4 | ENHANCING THERAPEUTIC EFFECTIVENESS OF NITRIC OXIDE INHALATION | GEN HOSPITAL CORP (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030202969-A1 | Enhancing therapeutic effectiveness of nitric oxide inhalation | THE GENERAL HOSPITAL CORPORATION | 2003-10-30 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| US-6601580-B1 | Enhancing therapeutic effectiveness of nitric oxide inhalation | THE GENERAL HOSPITAL CORPORATION | 2003-08-05 | — | — | US | claimed |
| EP-1301076-A2 | ENHANCING THERAPEUTIC EFFECTIVENESS OF NITRIC OXIDE INHALATION | THE GENERAL HOSPITAL CORPORATION (US) | 2003-04-16 | — | — | EP | claimed |
| WO-2002000175-A2 | ENHANCING THERAPEUTIC EFFECTIVENESS OF NITRIC OXIDE INHALATION | THE GENERAL HOSPITAL CORPORATION (US) | 2002-01-03 | — | — | WO | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | CYSLTR2 3061/4885CYSLTR1 3503/4885MAPT 97/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | CYSLTR2 3991/4885CYSLTR1 4303/4885MAPT 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.